<?xml version="1.0" encoding="UTF-8"?><faers xmlns="http://fda.gov/ns/faers"><meta><status>APPROVED</status><version>v2</version><patient-age>75</patient-age><report-id>PHEH2012US024060</report-id><gender>female</gender><reactions><reaction>Hemorrhoid</reaction><reaction>Bleeding from the rectum</reaction></reactions><drugs><drug><ndc>59572983</ndc><drug-name>EXELON PATCH</drug-name><manufacturer/><ingredients/></drug><drug><ndc>59572983</ndc><drug-name>ASPIRIN</drug-name><manufacturer/><ingredients/></drug><drug><ndc>59572983</ndc><drug-name>ATENOLOL</drug-name><manufacturer/><ingredients/></drug><drug><ndc>59572983</ndc><drug-name>POTASSIUM</drug-name><manufacturer/><ingredients/></drug><drug><ndc>59572983</ndc><drug-name>DIGOXIN</drug-name><manufacturer/><ingredients/></drug></drugs><outcomes/><country>United States</country><geo/></meta><original><ichicsr lang="en" xmlns="">
	<ichicsrmessageheader>
		<messagetype>ichicsr</messagetype>
		<messageformatversion>2.1</messageformatversion>
		<messageformatrelease>2.0</messageformatrelease>
		<messagenumb>4053160_286</messagenumb>
		<messagesenderidentifier>NovartisPH</messagesenderidentifier>
		<messagereceiveridentifier>ZZFDA</messagereceiveridentifier>
		<messagedateformat>204</messagedateformat>
		<messagedate>20121211134146</messagedate>
	</ichicsrmessageheader>
	<safetyreport>
		<safetyreportversion>1</safetyreportversion>
		<safetyreportid>PHEH2012US024060</safetyreportid>
		<primarysourcecountry>US</primarysourcecountry>
		<occurcountry>US</occurcountry>
		<transmissiondateformat>102</transmissiondateformat>
		<transmissiondate>2012-12-10</transmissiondate>
		<reporttype>1</reporttype>
		<serious code="1">Yes</serious>
		<seriousnessdeath>2</seriousnessdeath>
		<seriousnesslifethreatening>2</seriousnesslifethreatening>
		<seriousnesshospitalization>2</seriousnesshospitalization>
		<seriousnessdisabling>2</seriousnessdisabling>
		<seriousnesscongenitalanomali>2</seriousnesscongenitalanomali>
		<seriousnessother>1</seriousnessother>
		<receivedateformat>102</receivedateformat>
		<receivedate>2012-12-06</receivedate>
		<receiptdateformat>102</receiptdateformat>
		<receiptdate>2012-12-06</receiptdate>
		<additionaldocument>2</additionaldocument>
		<fulfillexpeditecriteria>1</fulfillexpeditecriteria>
		<companynumb>PHEH2012US024060</companynumb>
		<medicallyconfirm>2</medicallyconfirm>
		<primarysource>
			<reporterfamilyname>PRIVACY</reporterfamilyname>
			<reportercountry>US</reportercountry>
			<qualification code="5">Consumer or non-health professional</qualification>
		</primarysource>
		<primarysource>
			<reporterfamilyname>PRIVACY</reporterfamilyname>
			<reportercountry>US</reportercountry>
			<qualification code="1">Physician</qualification>
		</primarysource>
		<sender>
			<sendertype>1</sendertype>
			<senderorganization>NOVARTIS PHARMACEUTICAL CORPORATION</senderorganization>
			<senderdepartment>Clinical Safety and Epidemiology</senderdepartment>
			<senderfamilyname>Clinical Safety and Epidemiology</senderfamilyname>
			<senderstreetaddress>Novartis Pharmaceuticals Corp. Bldg 419, One Health Plaza</senderstreetaddress>
			<sendercity>East Hanover</sendercity>
			<senderstate>NJ</senderstate>
			<senderpostcode>07936</senderpostcode>
			<sendercountrycode>US</sendercountrycode>
			<sendertel>+1800378</sendertel>
			<sendertelextension>8567</sendertelextension>
			<sendertelcountrycode>US</sendertelcountrycode>
			<senderfax>+1973781</senderfax>
			<senderfaxextension>8001</senderfaxextension>
			<senderfaxcountrycode>US</senderfaxcountrycode>
			<senderemailaddress>gdss.configuration@pharma.novartis.com</senderemailaddress>
		</sender>
		<receiver>
			<receivertype>2</receivertype>
			<receiverorganization>ZZFDA</receiverorganization>
			<receiverdepartment>FDA</receiverdepartment>
			<receivertitle>Mr</receivertitle>
			<receivergivename>William</receivergivename>
			<receiverfamilyname>Taylor</receiverfamilyname>
			<receiverstreetaddress>5600 Fishers Lane Room 16B-45</receiverstreetaddress>
			<receivercity>Rockville</receivercity>
			<receiverstate>MD</receiverstate>
			<receiverpostcode>20857</receiverpostcode>
			<receivercountrycode>US</receivercountrycode>
			<receivertel>+1301827</receivertel>
			<receivertelextension>0964</receivertelextension>
			<receivertelcountrycode>US</receivertelcountrycode>
			<receiverfax>+1301594</receiverfax>
			<receiverfaxextension>0829</receiverfaxextension>
			<receiverfaxcountrycode>US</receiverfaxcountrycode>
			<receiveremailaddress>.</receiveremailaddress>
		</receiver>
		<patient>
			<patientinitial>NF</patientinitial>
			<patientbirthdateformat>102</patientbirthdateformat>
			<patientbirthdate>19371201</patientbirthdate>
			<patientsex code="2">Female</patientsex>
			<reaction>
				<primarysourcereaction>Hemorrhoid</primarysourcereaction>
				<reactionmeddraversionllt>15.1</reactionmeddraversionllt>
				<reactionmeddrallt>Hemorrhoids</reactionmeddrallt>
				<reactionmeddraversionpt>15.1</reactionmeddraversionpt>
				<reactionmeddrapt>Haemorrhoids</reactionmeddrapt>
				<reactionoutcome code="6">unknown</reactionoutcome>
			</reaction>
			<reaction>
				<primarysourcereaction>Bleeding from the rectum</primarysourcereaction>
				<reactionmeddraversionllt>15.1</reactionmeddraversionllt>
				<reactionmeddrallt>Rectal bleeding</reactionmeddrallt>
				<reactionmeddraversionpt>15.1</reactionmeddraversionpt>
				<reactionmeddrapt>Rectal haemorrhage</reactionmeddrapt>
				<reactionoutcome code="6">unknown</reactionoutcome>
			</reaction>
			<drug>
				<drugcharacterization code="1">suspsect</drugcharacterization>
				<medicinalproduct>EXELON PATCH</medicinalproduct>
				<obtaindrugcountry>US</obtaindrugcountry>
				<drugauthorizationnumb>22-083</drugauthorizationnumb>
				<drugauthorizationcountry>US</drugauthorizationcountry>
				<drugauthorizationholder>NOVARTIS SECTOR: PHARMA</drugauthorizationholder>
				<drugstructuredosagenumb>4.5</drugstructuredosagenumb>
				<drugstructuredosageunit code="003">milligrams</drugstructuredosageunit>
				<drugdosagetext>4.5 mg, Daily</drugdosagetext>
				<drugdosageform normalized="trans-therapeutic-system">Trans-therapeutic-system</drugdosageform>
				<drugadministrationroute code="062">Transdermal</drugadministrationroute>
				<actiondrug code="5">Unknown</actiondrug>
				<drugrecurreadministration code="3">Unknown</drugrecurreadministration>
				<drugadditional code="Dose=4.5mg/24hours Freq= Route= ExpDt="/>
				<activesubstance>
					<activesubstancename>RIVASTIGMINE</activesubstancename>
				</activesubstance>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Haemorrhoids</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Not assessable</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Haemorrhoids</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Suspected</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Rectal haemorrhage</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Not assessable</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Rectal haemorrhage</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Suspected</drugresult>
				</drugreactionrelatedness>
			</drug>
			<drug>
				<drugcharacterization code="1">suspsect</drugcharacterization>
				<medicinalproduct>ASPIRIN</medicinalproduct>
				<obtaindrugcountry>US</obtaindrugcountry>
				<drugauthorizationcountry>US</drugauthorizationcountry>
				<actiondrug code="5">Unknown</actiondrug>
				<drugrecurreadministration code="3">Unknown</drugrecurreadministration>
				<activesubstance>
					<activesubstancename>ACETYLSALICYLIC ACID</activesubstancename>
				</activesubstance>
			</drug>
			<drug>
				<drugcharacterization code="2">concomitant</drugcharacterization>
				<medicinalproduct>ATENOLOL</medicinalproduct>
				<obtaindrugcountry>US</obtaindrugcountry>
				<drugauthorizationcountry>US</drugauthorizationcountry>
				<actiondrug code="5">Unknown</actiondrug>
				<drugrecurreadministration code="3">Unknown</drugrecurreadministration>
				<drugadditional code="Dose= Freq= Route= ExpDt="/>
				<activesubstance>
					<activesubstancename>ATENOLOL</activesubstancename>
				</activesubstance>
			</drug>
			<drug>
				<drugcharacterization code="2">concomitant</drugcharacterization>
				<medicinalproduct>POTASSIUM</medicinalproduct>
				<obtaindrugcountry>US</obtaindrugcountry>
				<drugauthorizationcountry>US</drugauthorizationcountry>
				<actiondrug code="5">Unknown</actiondrug>
				<drugrecurreadministration code="3">Unknown</drugrecurreadministration>
				<drugadditional code="Dose= Freq= Route= ExpDt="/>
				<activesubstance>
					<activesubstancename>POTASSIUM</activesubstancename>
				</activesubstance>
			</drug>
			<drug>
				<drugcharacterization code="2">concomitant</drugcharacterization>
				<medicinalproduct>DIGOXIN</medicinalproduct>
				<obtaindrugcountry>US</obtaindrugcountry>
				<drugauthorizationcountry>US</drugauthorizationcountry>
				<actiondrug code="5">Unknown</actiondrug>
				<drugrecurreadministration code="3">Unknown</drugrecurreadministration>
				<drugadditional code="Dose= Freq= Route= ExpDt="/>
				<activesubstance>
					<activesubstancename>DIGOXIN</activesubstancename>
				</activesubstance>
			</drug>
			<summary>
				<narrativeincludeclinical>Case number PHEH2012US024060, is an <Semaphore x="1938518" class="Disease or Finding" value="First-Degree Burn" score="1.00" ID="C76130">initial </Semaphore>spontaneous report received from a consumer on 06 Dec 2012. This report refers to a 75-year old female patient. Concomitant medications included <Semaphore x="168570" class="Medicine" value="Atenolol" score="0.49" ID="213117">atenolol </Semaphore>(<Semaphore x="2199623" class="Occupation" value="Manufacturer" score="1.00" ID="C25392">manufacturer </Semaphore>unknown), <Semaphore x="1848940" class="Procedure" value="Dietary Protocol" score="1.00" ID="C93051">potassium </Semaphore>(<Semaphore x="2199623" class="Occupation" value="Manufacturer" score="1.00" ID="C25392">manufacturer </Semaphore>unknown) and <Semaphore x="470506" class="Medicine" value="Digoxin" score="0.49" ID="256879">digoxin </Semaphore>(<Semaphore x="2199623" class="Occupation" value="Manufacturer" score="1.00" ID="C25392">manufacturer </Semaphore>unknown). The patient received <Semaphore x="560518" class="Medicine" value="Exelon" score="0.74" ID="249270">Exelon </Semaphore>(<Semaphore x="1142851" class="Medicine" value="rivastigmine" score="0.49" ID="239962">rivastigmine</Semaphore>) transdermal patches for the <Semaphore x="2610768" class="Procedure" value="Therapeutic Procedure" score="1.00" ID="C49236">treatment </Semaphore>of an unspecified indication from an unspecified date at a dose of 4.5 mg daily. The patient also received <Semaphore x="166901" class="Medicine" value="Aspirin" score="0.74" ID="212518">aspirin </Semaphore>(<Semaphore x="2199623" class="Occupation" value="Manufacturer" score="1.00" ID="C25392">manufacturer </Semaphore>unknown) for unspecified indication from an unspecified date and at an unspecified dose. On an unspecified date, the patient experienced <Semaphore x="2988829" class="MedDRA LLT" value="Haemorrhage" score="1.00" ID="10055798">bleeding </Semaphore>from the <Semaphore x="2449748" class="AnatomicStructure" value="Rectum" score="1.00" ID="C12390">rectum </Semaphore>for about six weeks off and on. The reporter also reported that it might be due to the mixing both <Semaphore x="560518" class="Medicine" value="Exelon" score="0.74" ID="249270">Exelon </Semaphore>patch and <Semaphore x="166901" class="Medicine" value="Aspirin" score="0.74" ID="212518">aspirin</Semaphore>. The patients <Semaphore x="2398439" class="Occupation" value="Physician" score="1.00" ID="C25741">physician </Semaphore>also confirmed that the patient have <Semaphore x="2016276" class="Disease or Finding" value="Hemorrhoidal Hemorrhage" score="1.00" ID="C78337">haemorrhoids</Semaphore>. The <Semaphore x="2353201" class="Disease or Finding" value="Outcome" score="1.00" ID="C20200">outcome</Semaphore>, seriousness and causality were not reported.</narrativeincludeclinical>
				<sendercomment>Medical assessment comment: Review of available reported data does not allow for a proper causality assessment.</sendercomment>
			</summary>
		</patient>
	</safetyreport>
</ichicsr></original></faers>